IrisVision Sees a Brighter Future

Our lifestyle-friendly devices and personalized services are designed to provide easy, complete solutions for the full range of low vision conditions. At IrisVision, our vision is to improve yours.

About IrisVision

IrisVision designs and builds wearable devices that enable at-risk and visually impaired people to see. Our products leverage cutting-edge healthcare technology to allow low vision persons to maintain their independence, perform their daily activities, and enjoy the visual world around them.

Our Mission

IrisVision envisions a world where vision health solutions are seamlessly integrated into daily living and are accessible to everyone around the globe.

We are on a mission to help even the most challenged patients with their vision conditions. Our goal is to preserve and improve the vision experience of low vision persons. IrisVision seeks to forge new frontiers for the delivery of care at the intersection of digital health and vision science.

Our Story

IrisVision’s quest began in 2014, when Co-Founder Frank Werblin, Ph.D. — a Guggenheim Fellow and UC Berkeley professor of neuroscience for more than 40 years — discovered a number of cellular associations underlying visual information processing in the retina. His work on retinal chip implants to help the blind see led him to seek a solution that was less invasive and more affordable — a tool accessible to the wider low-vision community worldwide.

A chance encounter with a man whose daughter was challenged with low vision led to an unexpected offer: funding for the development of an invention to help those who have lost most, but not all, of their sight. Dr. Werblin got to work on this exciting concept for IrisVision, securing a grant from the National Eye Institute, and collaborating with experts at Johns Hopkins University.

Along the way, Dr. Werblin connected with Co-Founder and CEO Ammad Khan, who brought a wealth of experience in the mobile and augmented reality technology fields. Together, Werblin and Khan formed a company to leverage Dr. Werblin’s years of clinical lab research, create a scalable application, and bring revolutionary new solutions to low vision patients everywhere.

IrisVision was incorporated in 2016, and delivered its first commercial low vision assistive device to consumers in 2017. As of today, there are approximately three and half thousand people using IrisVision products to see and achieve a quality of life that they thought had lost.

IrisVision’s aspirations have grown to not just help, but prevent vision loss. By expanding access between patients and providers, and delivering earlier and more frequent patient insights directly to clinicians’ desktops, IrisVision sees the potential to save the sight of 93 million adults in the United States alone who are at high risk of serious vision loss.